Fuzz ... hard to see why you would conclude Covid P2 early and focus on P3 unless there was good reason from P2?

A contrarian position though, could also be low impact in P2 due to lower severity of Omicron on the wider population, and a desire to get to the real goods and positioning for "long haul" though? The P3 seems equally or more focused on the longer term detriment of Covid on higher risk patients if I read that correctly ... those over 65 and/or with other pre-exiting health concerns especially cardio. This is an area where ABL could really shine, the longer term Covid threat with unhealthy patients. Although, I still do have hopes that ABL can be helpful, very helpful, should a more severe Covid strain appear or :reappear" like with the Delta rumored resurgence.

Hopefully the Covid P2 is showing enough benefit to appley for EUA, and onward to P3 and BoM2. That would be a BIG win if we can get EUA plus rapidly advance those other 2 important studies.

Let's see what the market thinks today, and this week, as the news of this development and annoncement spreads and the chatter and speculation reactions occur.